R&D Executives

VClinBio was founded in the year 2013. Management include R&D executives that held academic and leadership positions in discovery and development and also with extensive healthcare investment and administration experience.

Discovery & Development Team

Subbu Apparsundaram, PhD, CEO/CSO

Dr. Subbu Apparsundaram, Chief Executive Officer, is an established scientist with extensive experience in drug discovery pharmacology, neuroscience, and immunology. He has solid experience in conceptualizing, formulating and implementing basic science to drug discovery strategies. He is highly skilled in target validation, lead identification and clinical candidate selection. Prior to founding V ClinBio, he was a Drug Discovery Scientist at Hoffmann-La Roche Pharmaceuticals where he provided team leadership for neuroscience and inflammation projects and enabled research teams to achieve lead selection, lead optimization and clinical candidate selection milestones. He was also a faculty at the University of Kentucky Medical Center. He has published several peer reviewed research papers.


Satwant K. Narula, PhD, Drug Discovery & Development

Satwant’s major research focus has always been on New Drug Discovery and Development. Expertise base comprises a successful track record in progressing Biological drugs and small molecule therapeutics into the Clinic with a strong focus on personalized health care/biomarker approach to drug development. She led over 20 molecules into clinical development. Disease areas of focus have included autoimmune diseases, Respiratory diseases, fibrosis, infectious diseases, immune tolerance and cancer immunotherapy. Satwant was Vice President at Bristol-Myers Squibb, Roche Pharmaceuticals, and Schering-Plough. Over the course of her career in Schering-Plough, she was involved in programs that resulted in marketed drugs such as IntronA, Remicade and Posaconazole.


Gerry Higgins, MD, PhD, Neurology

Dr. Higgins is a well-known clinician, scientist and an entrepreneur with over 30 years of experience in biomedical research. Dr. Higgins Served as Vice President for Hoffmann-La Roche Pharmaceuticals, helping to integrate personalized medicine into their product line. He also served as Chief of Molecular Neurobiology at the NIH, supervised several laboratories, and managed multimillion annual budget. Obtained over $65 M in grants, contracts and corporate funding for R&D projects.He also served as Chief of Molecular Neurobiology at the National Institutes of Health, Vice President of Hoffmann – La Roche, Vice President of Laerdal Medical Corporation, Chief Innovation Officer for the MedStar Hospital Network, Adjunct Professor at Harvard Medical School, Professor at University of Rochester School of Medicine and was Director at Assurex Health. Currently, Dr. Higgins is a Research Professor at University of Michigan.Dr. Higgins has a two Ph.D. degrees (Neuroscience & Anatomy) and a M.D. degree in Psychiatry from the University of Vermont. He has authored over 330 peer-reviewed publications, books and technical monographs, and a patent to his credit. He is a member of American Psychiatric Association, American Society of Human Genetics, American Society for Clinical Pharmacology and Therapeutics, and American Medical Informatics Association.


Narayanan Surenderan, PhD, Pharmacokinetics

Dr. Narayanan Surendran (Suri) has extensive drug discovery and development experience with specialization in ADME cross all therapeutic areas, including hit to lead characterization for several projects. Suri is President of RythRx Therapeutics and Consultant at TSRL Inc. Previously, Suri was Director of Pharmacokinetics at Pfizer Global Research and Development (USA), and Vice President of Drug Metabolism and Pharmacokinetics (DMPK) for Orchid Research Laboratories Limited (India). He also was at Parke Davis and DuPont Merck, executing DMPK projects for NCEs. He led projects involving prodrug development and NAFLD research. He obtained his PhD at University of Arizona and has several patents and peer-reviewed research publications.


Navaneetha Rao, ScD, Regulatory Affairs & Clinical Research

Dr. Rao has hands-on regulatory and clinical experience with integrated drug development of biologics (gene and cell transfer products), therapeutic proteins, mAbs, small molecules, and generics for indications in cardiology, oncology, infectious disease, and transfusion medicine. He has over 15 years of industry experience including managing direct reports, leading international teams at both sponsor organizations and full service CROs, and providing strategic advice to biotech startups, established pharmaceuticals, and international organizations. He is experienced in 505(b)(2) development pathway, advancing NMEs and implementing GLP/GCP quality assurance. Previously, Dr. Rao was VP of Clinical R&D at Vicus Therapeutics, Cato Research, and Reliance Life Sciences. Recently, he has been COO of RythRx. He obtained his Doctor of Science degree at the Harvard University, and has several peer-reviewed research publications.


Thani Jambulingam, PhD, Pharmaceutical Marketing

Dr. Thani Jambulingam is a well-recognized and established scholar in Pharmaceutical and Healthcare Marketing. He has designed supply chain network for small molecules, biologics and imaging products for pharmaceutical companies. He also has developed pricing strategy for pharmaceutical products, and develops pharmaceutical marketing strategy, and entrepreneurial orientation. He has delivered a multi-million dollar growth opportunity strategy workshop to the leadership team of a leading global pharmaceutical company. He has developed market potential analysis and forecasting for a global vaccine. He obtained his PhD and MS degrees at the University of Wisconsin, Madison, Wisconsin, USA. Currently, he is an Associate Professor at the Haub School of Business at Saint Joseph’s University in Philadelphia, Pennsylvania, USA. He has trained pharmaceutical executives and served in dissertation committees in marketing at Columbia University. He has been quoted in Financial Times, Bloomberg, and Boston Globe among others. He has published several peer reviewed research papers.